The Swiss pharmaceutical company said Friday that the oncologic drugs advisory committee had voted 11 to two in favor of Polivy in combination with Rituxan plus cyclophosphamide, doxorubicin and prednisone to treat the disease, though the move isn’t binding.
More Stories
CDs paying 5% are a dying breed. Here’s how to find high savings rates while you still can.
Many 5% CDs are going away in the weeks after the Fed’s first interest-rate cut. Some have already disappeared.
Stocks poised for first September gain in 5 years. Why more good times could lie ahead.
September has historically been the worst month for U.S. stocks — but not this year
This mortgage hack could save you thousands a year — and it’s not a refinance
Homeowners looking to leverage lower mortgage rates can ask their lenders for a “rate modification,” financial experts say.
Diversify your 401(k) with these cheap investments that nobody else wants right now
It’s rescued investors in the past from a lost decade
Stock investors face a gut-wrenching 3 months ahead after record market run
‘There’s this debate between a hard landing, a soft landing or no landing that continues,’ says Lerner at Truist Advisory...
Gold’s record rally gets added jolt from Fed rate cut. Is there anyone left to buy?
Some analysts warn the pool of potential gold buyers could begin to run dry.